Showing results (971-980 of 4,514) with videos related to
Sort By:
Pageof 452
Future Oncology (London, England)|December 16, 2025
Efficacy and safety of radiotherapy plus immunochemotherapy in patients with oligometastatic esophageal cancerYanan Duan, Shuping Cheng, Wenru Qin, et al.Future Oncology (London, England)|December 24, 2025
Artificial intelligence in breast cancer: clinical applications in diagnosis, prognosis, and therapeuticsJanhvi Singh, Omar Awad Alsaidan, Alhussain Aodah, et al.Future Oncology (London, England)|December 12, 2025
A retrospective chart review of UK patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumabTom Geldart, Lisa Pickering, Anand Sharma, et al.Future Oncology (London, England)|June 18, 2025
Effects and safety of TMZ plus RT combined with other drugs in the treatment of glioblastoma: a network meta-analysisSimin Wang, Jiyong Wu, Wenfei Zhang, et al.Future Oncology (London, England)|February 13, 2025
Oncologists' and urologists' preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experimentCaroline Vass, Cathy Anne Pinto, Kelley Myers, et al.Future Oncology (London, England)|February 12, 2025
Asciminib in the treatment of chronic myeloid leukemia in chronic phaseAlessandro Costa, Emilia Scalzulli, Maria Laura Bisegna, et al.Future Oncology (London, England)|December 18, 2024
Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinomaGuangming Yi, Fanghao Cai, Liangzhong Liu, et al.Future Oncology (London, England)|December 26, 2024
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancerJohn H Strickler, Tanios Bekaii-Saab, Andrea Cercek, et al.Future Oncology (London, England)|December 21, 2024
CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in JapanTakahiro Nakayama, Linghua Xu, Yasuaki MuramatsuFuture Oncology (London, England)|December 23, 2024
Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?Antoine Mouawad, Marc Boutros, Antoine Chartouni, et al.Pageof 452